NASDAQ:ASND - Ascendis Pharma A/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$65.29 +1.77 (+2.79 %)
(As of 12/14/2018 01:07 PM ET)
Previous Close$63.52
Today's Range$62.78 - $65.54
52-Week Range$36.38 - $76.99
Volume9,542 shs
Average Volume92,627 shs
Market Capitalization$2.63 billion
P/E Ratio-15.08
Dividend YieldN/A
Beta0.82
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.

Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASND
Previous Symbol
CUSIPN/A
Phone45-7022-2244

Debt

Debt-to-Equity RatioN/A
Current Ratio10.54
Quick Ratio10.54

Price-To-Earnings

Trailing P/E Ratio-15.08
Forward P/E Ratio-16.28
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.80 million
Price / Sales1,524.52
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.82 per share
Price / Book11.22

Profitability

EPS (Most Recent Fiscal Year)($4.33)
Net Income$-140,040,000.00
Net Margins-38,569.44%
Return on Equity-45.44%
Return on Assets-41.61%

Miscellaneous

Employees137
Outstanding Shares42,030,000
Market Cap$2.63 billion
OptionableOptionable

Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) released its earnings results on Wednesday, November, 28th. The biotechnology company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.29. The biotechnology company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.16 million. Ascendis Pharma A/S had a negative net margin of 38,569.44% and a negative return on equity of 45.44%. View Ascendis Pharma A/S's Earnings History.

When is Ascendis Pharma A/S's next earnings date?

Ascendis Pharma A/S is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for Ascendis Pharma A/S.

What price target have analysts set for ASND?

9 brokers have issued 12 month target prices for Ascendis Pharma A/S's shares. Their predictions range from $60.00 to $88.00. On average, they expect Ascendis Pharma A/S's share price to reach $78.25 in the next twelve months. This suggests a possible upside of 19.8% from the stock's current price. View Analyst Price Targets for Ascendis Pharma A/S.

What is the consensus analysts' recommendation for Ascendis Pharma A/S?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ascendis Pharma A/S.

Has Ascendis Pharma A/S been receiving favorable news coverage?

News headlines about ASND stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ascendis Pharma A/S earned a news impact score of 1.8 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the company's share price in the next several days.

Are investors shorting Ascendis Pharma A/S?

Ascendis Pharma A/S saw a increase in short interest in November. As of November 30th, there was short interest totalling 820,896 shares, an increase of 29.9% from the November 15th total of 631,710 shares. Based on an average trading volume of 110,197 shares, the days-to-cover ratio is currently 7.4 days. Approximately 2.3% of the shares of the stock are short sold. View Ascendis Pharma A/S's Current Options Chain.

Who are some of Ascendis Pharma A/S's key competitors?

Who are Ascendis Pharma A/S's key executives?

Ascendis Pharma A/S's management team includes the folowing people:
  • Mr. Michael Wolff Jensen, Chairman, Sr. VP & Gen. Counsel (Age 47)
  • Mr. Jan Møller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 58)
  • Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 44)
  • Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 49)
  • Dr. Harald Rau, Sr. VP & Chief Scientific Officer (Age 48)

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (9.88%), Alliancebernstein L.P. (1.70%), Marshall Wace North America L.P. (1.67%), Franklin Resources Inc. (1.41%), BlackRock Inc. (1.10%) and First Manhattan Co. (0.65%).

Which institutional investors are selling Ascendis Pharma A/S stock?

ASND stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, First Manhattan Co., Allianz Asset Management GmbH, Foresite Capital Management IV LLC, Renaissance Technologies LLC, Marshall Wace LLP, Matisse Capital and University of Notre Dame DU Lac.

Which institutional investors are buying Ascendis Pharma A/S stock?

ASND stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Putnam Investments LLC, Loomis Sayles & Co. L P, FIL Ltd, Marshall Wace North America L.P., Fosun International Ltd, Franklin Resources Inc. and DekaBank Deutsche Girozentrale.

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $65.29.

How big of a company is Ascendis Pharma A/S?

Ascendis Pharma A/S has a market capitalization of $2.63 billion and generates $1.80 million in revenue each year. The biotechnology company earns $-140,040,000.00 in net income (profit) each year or ($4.33) on an earnings per share basis. Ascendis Pharma A/S employs 137 workers across the globe.

What is Ascendis Pharma A/S's official website?

The official website for Ascendis Pharma A/S is http://www.ascendispharma.com.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 5, HELLERUP G7, 2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]


MarketBeat Community Rating for Ascendis Pharma A/S (NASDAQ ASND)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  382
MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma A/S and other stocks. Vote "Outperform" if you believe ASND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel